Tau蛋白在阿尔茨海默病中的发病机制及治疗策略进展  

Advances in the Pathogenesis and Therapetic Strategies of Tau Proteins in Alzheimer’s Disease

作　　者：郑晴晴 刘煜[1] 

机构地区：[1]中国药科大学生命科学与技术学院,江苏 南京

出　　处：《药物资讯》2025年第2期129-138,共10页Pharmacy Information

摘　　要：阿尔茨海默病(Alzheimer disease;AD)是一种慢性神经退行性疾病,以脑部变化为特征,导致记忆力、思维能力、行为和社会技能持续下降,最终影响患者的自理能力,主要发病机制由β-淀粉样蛋白(amyloid β-protein;Aβ)和Tau蛋白聚集沉积及两者相互作用所导致。Tau蛋白是一种微管相关蛋白,有助于神经元内部稳定,但病理性Tau蛋白会引起包括阿尔茨海默病在内的神经系统疾病,而且发现Tau蛋白与阿尔茨海默病患者认知水平存在正相关性。本文旨在讨论Tau蛋白在AD患者中的发病机制,以及靶向Tau的阿尔茨海默病的最新治疗策略。Alzheimer’s disease is a chronic neurodegenerative disorder characterized by brain changes that lead to a continuous decline in memory, thinking ability, behavior, and social skills, ultimately affecting the patient’s ability to take care of themselves. The main pathogenic mechanisms are caused by the aggregation and deposition of amyloid β-protein, Tau proteins, and the Aβ and Tau protein aggregation and deposition and their interaction. Tau protein is a microtubule-associated protein that contributes to internal stabilization of neurons. However, pathological Tau protein can cause neurological disorders, including Alzheimer’s disease, and it has been found that there is a positive correlation between Tau protein and the cognitive level of Alzheimer’s disease patients. This article aims to discuss the pathogenic mechanisms of Tau protein in Alzheimer’s disease patients and the latest treatment strategies for Alzheimer’s disease targeting Tau.

关 键 词：阿尔茨海默病 TAU蛋白 发病机制 治疗策略 

分 类 号：R741[医药卫生—神经病学与精神病学]